Trial intelligence / Profile preview

Open-label phase II sequential Taxotere followed by Myocet + cyclophosphamide in newly diagnosed HER2-negative breast cancer

2007-005173-56Phase 2Completed

Sponsor: Grupo Oncológico Gallego
Start: Jan 2008
Modality: Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of docetaxel, doxorubicin and cyclophosphamide in breast cancer, sponsored by Grupo Oncológico Gallego. Primary endpoints: pathological complete response rate and objective clinical response rate. Started Jan 2008; status: completed.

Drugs

docetaxeldoxorubicincyclophosphamide

Conditions

breast cancer

Beyond the preview

Go deeper on 2007-005173-56.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-005173-56.